From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
(RS)-Reproterol Structural Formula V1.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
Inhalation (MDI), IV
ATC code
Legal status
Legal status
  • DE: § 48 AMG/§ 1 MPAV (Prescription only)
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.053.579 Edit this at Wikidata
Chemical and physical data
Molar mass389.406 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2][3]

It was patented in 1965 and came into medical use in 1977.[4]


Reproterol is chiral, so it contains a stereocenter. There are thus two enantiomers, the ( R ) - form and the ( S ) - form. The commercial preparations contain the drug as racemate (1: 1 mixture of enantiomers).[5]

Enantiomers of Reproterol
(R)-Reproterol Structural Formula V1.svg
CAS-Nummer: 210710-33-1
(S)-Reproterol Structural Formula V1.svg
CAS-Nummer: 210710-34-2


  1. ^ Küpper, T; Goebbels, K; Kennes, LN; Netzer, NC (December 2012). "Cromoglycate, reproterol, or both—what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635.
  2. ^ Virchow JC Jr. Reproterol: beta-2-agonist, theophylline, or both? Respiration. 1999;66(3):210-1. PMID 10364735
  3. ^ Virchow JC, Jr (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; international review of thoracic diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735.
  4. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
  5. ^ Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 196.